Member Info for Peleliu

https://www.marketscreener.com/quote/stock/GSK-PLC-9590199/news/Goldman-Sachs-Resumes-GlaxoSmithKline-at-Buy-43096876/

In a research note, Goldman Sachs analyst Keyur Parekh has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at GBX 2000.

https://www.fiercepharma.com/pharma/gsk-was-warned-repeatedly-about-zantac-risks-didnt-act-warnings-bloomberg

For those with a subscription to the Financial Times:

https://on.ft.com/3GUa5KP

https://www.bloomberg.com/news/articles/2022-11-27/southern-africa-s-biggest-dam-halts-power-generation-to-zimbabwe?sref=melRK1Xn

https://www.bloomberg.com/news/articles/2022-09-30/zimbabwe-wants-half-of-royalties-paid-in-gems-precious-metals?cmpid=BBD093022_CEU&utm_medium=email&utm_source=newsletter&utm_term=220930&utm_campaign=closeeurope&sref=melRK1Xn

https://www.breakingviews.com/considered-view/big-pharma-should-brace-for-worst-cancer-outcome/

https://www.bloomberg.com/news/articles/2022-08-16/astra-sues-to-block-top-dealmaker-sharing-therapy-info-with-gsk?sref=melRK1Xn

https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation/

BUZZ-GSK, Sanofi: "Zantac has arrived" - Reuters News

11-Aug-2022 07:45:37
** GSK, Sanofi and Haleon remain in spotlight after heavy drop in previous session on rumours fuelling concern over potential negative implication from lawsuits in the U.S. over Zantac, a drug that was withdrawn in 2019
** "Zantac has arrived," writes Deutsche Bank on GSK/Sanofi
** "We don't think the evidence points to this as another glyphosate, but it is very possible we may see a liability of some $bn magnitude incurred which, coupled with negative headlines from the slate of imminently pending cases... is likely to act as a short-term headwind (already has?)," it adds
** Credit Suisse sees Haleon's involvement in Zantac litigation as limited. It adds: "more than 2,000 cases have been filed in the US and the first trial begins on 22 August 2022"
** One trader sees shares in GSK, Sanofi and Haleon rebounding. GSK up 1.4%, Sanofi up 0.9%, Haleon down 2% on Tradegate

(Reporting by Danilo Masoni)
(( Danilo.Masoni@TR.com ))

BUZZ-GSK, Sanofi: "Zantac has arrived" - Reuters News

11-Aug-2022 07:45:37
** GSK, Sanofi and Haleon remain in spotlight after heavy drop in previous session on rumours fuelling concern over potential negative implication from lawsuits in the U.S. over Zantac, a drug that was withdrawn in 2019
** "Zantac has arrived," writes Deutsche Bank on GSK/Sanofi
** "We don't think the evidence points to this as another glyphosate, but it is very possible we may see a liability of some $bn magnitude incurred which, coupled with negative headlines from the slate of imminently pending cases... is likely to act as a short-term headwind (already has?)," it adds
** Credit Suisse sees Haleon's involvement in Zantac litigation as limited. It adds: "more than 2,000 cases have been filed in the US and the first trial begins on 22 August 2022"
** One trader sees shares in GSK, Sanofi and Haleon rebounding. GSK up 1.4%, Sanofi up 0.9%, Haleon down 2% on Tradegate

(Reporting by Danilo Masoni)
(( Danilo.Masoni@TR.com ))

https://miningzimbabwe.com/zimbabwean-man-to-be-caledonias-biggest-share-holder/

https://polaris.brighterir.com/public/baker_steel_resources_trust/news/rns/story/w31oj2x

In fact, Liberum raised the target price post the production update earlier this week.

CALEDONIA MINING CORPORATION PLC CALq.L: LIBERUM RAISES TARGET PRICE TO 1421P FROM 1380P - Reuters News

https://*********************/companies/usa/industrial-metals-nonferrous/caledonia-mining-corporation-plc/research/liberum/liberum-caledonia-mining-initiation-ugly-duckling-becoming-a-golden-swan-in-zimbabwe/1_4453036e-1c34-4693-b67b-969d92f4e7c6

https://www.bloomberg.com/news/articles/2022-06-15/wealth-shock-delays-gold-bull-market-as-goldman-revises-targets?sref=melRK1Xn

Unless there are any near term catalysts to drive the share price and re-invigorate some momentum in it, the only option will be to continue to gradually raise the dividend. Otherwise this will continue trading like a government bond.

https://www.bloomberg.com/news/articles/2022-05-07/zimbabwe-imposes-capital-controls-to-stem-currency-s-slide?srnd=premium-europe&sref=melRK1Xn

A statement from the Company whether and what the implications are for the business, if any, would be helpful.

Shot across the bow for Mark Learmonth!

https://www.bloomberg.com/news/videos/2022-03-09/goldman-s-currie-sees-perfect-storm-for-gold-video?sref=melRK1Xn

https://www.bloomberg.com/news/articles/2022-02-23/gold-fights-off-rising-rates-bitcoin-to-be-haven-in-tough-times?srnd=premium-europe&sref=melRK1Xn